Help Pharmacy Medical Leadership and Credentials: An Independent Review

What Is Help Pharmacy and Who Runs It?

Help Pharmacy operates as both a 503A compounding pharmacy and a 503B outsourcing facility under Texas and federal law. The 503B designation, created by the Drug Quality and Security Act of 2013, allows a compounder to produce drug products without patient-specific prescriptions for distribution to licensed practitioners, provided the facility registers with the FDA and complies with current good manufacturing practice (cGMP) standards. The FDA maintains a public list of registered 503B outsourcing facilities, and Help has appeared on that list.

Leadership Structure

Help Pharmacy was founded by pharmacist Luke Witt and has grown into one of the largest compounding operations in the United States. Day-to-day pharmacy operations are overseen by licensed pharmacists-in-charge (PICs), a role regulated by the Texas State Board of Pharmacy. The PIC is personally accountable for compliance with state pharmacy law under Texas Occupations Code Chapter 558.

The company does not publicly list individual medical or pharmacy director biographies on its main website as of this writing, which is a meaningful gap relative to PCAB standards that expect transparent quality leadership documentation. Prescribers evaluating Help should request the current PIC's name and license number and verify it against the TSBP license lookup tool.

Ownership and Scale

Help describes itself as the largest compounding pharmacy in the United States by volume. Independent verification of that claim is difficult. What is verifiable: the Houston facility covers hundreds of thousands of square feet, the company ships to all 50 states, and it employs hundreds of pharmacy staff. Scale matters for quality risk, because larger 503B operations face higher FDA scrutiny and more complex cGMP obligations than a small neighborhood compounding shop.

State Licensure and Texas State Board of Pharmacy Standing

A pharmacy's home-state license is the foundational credential any patient or prescriber should verify first.

Help Pharmacy holds an active pharmacy permit issued by the Texas State Board of Pharmacy. The TSBP publishes disciplinary actions online at tsbp.texas.gov. Consumers and clinicians can search for formal complaints, consent orders, or license revocations. As of the date of this review, Help has not appeared on TSBP's public disciplinary action list with a license revocation or suspension, though the absence of formal discipline does not mean zero complaints have been filed.

Multi-State Licensing

Because Help ships to all 50 states, it is required to hold non-resident pharmacy permits in each destination state. Non-resident permits are issued by each state's pharmacy board and can be verified independently. Failure to hold a valid non-resident permit in a given state would make that shipment technically illegal, a risk telehealth platforms should audit before routing prescriptions to any compounding pharmacy.

Pharmacist-in-Charge Accountability

Under 21 CFR Part 4 and Texas pharmacy rules, the PIC must ensure that compounding practices meet safety, potency, and sterility standards. If the PIC changes (a common event in high-growth pharmacy operations), the quality culture of the operation may shift. Prescribers relying on Help for sterile injectables such as semaglutide vials or BPC-157 should ask Help's pharmacy liaison for current PIC credentials annually.

FDA Registration and 503B Compliance History

This section covers the most consequential credentialing question for any 503B compounder supplying sterile injectables.

The FDA inspects registered 503B outsourcing facilities and issues Form 483 observations when investigators find conditions that may constitute violations of the Federal Food, Drug, and Cosmetic Act. A Form 483 is not a warning letter and does not constitute a finding of adulteration, but it does signal areas of regulatory concern that the facility must address in a written response.

Form 483 Observations

Help Pharmacy's 503B facility received Form 483 observations during FDA inspections. The FDA posts inspection records through its Establishment Inspection Report database. The specific observations cited in those records have included data integrity concerns and environmental monitoring gaps in sterile manufacturing areas. Those categories are serious in any cGMP context because they bear directly on whether sterile injectable products are being prepared safely.

Help filed corrective action responses to each Form 483. The FDA's review of those responses is ongoing under normal regulatory timelines. No consent decree of permanent injunction has been issued against Help as of this article's review date. A consent decree would represent a far more severe enforcement action and would typically require court-supervised remediation.

The Semaglutide Shortage Designation Issue

503B facilities may compound a drug only when it appears on the FDA's drug shortage list. The FDA added semaglutide (Ozempic, Wegovy) to the shortage list in 2022, which allowed 503B compounders including Help to produce compounded semaglutide at scale. The FDA removed injectable semaglutide from the shortage list in early 2025, triggering a compliance wind-down period for 503B facilities.

That removal is the single most important regulatory development affecting Help's compounded semaglutide business. After the shortage ends and the FDA's grace period closes, a 503B facility can no longer legally compound and distribute semaglutide without patient-specific prescriptions under the 503A pathway, and even 503A compounding of a commercially available drug in a dosage form that is not essentially a copy requires specific clinical justification.

Prescribers and patients sourcing compounded semaglutide from Help after the shortage removal date should ask for written documentation of the legal pathway under which each shipment is being dispensed. The FDA's compounding guidance documents provide the relevant regulatory framework.

PCAB Accreditation: What It Means and Its Limits

The Pharmacy Compounding Accreditation Board (PCAB), now administered by URAC, sets voluntary quality standards for compounding pharmacies. PCAB accreditation requires a site survey, review of standard operating procedures, and ongoing compliance with USP <795> (non-sterile) and USP <797> (sterile) standards.

Help Pharmacy has held PCAB accreditation. PCAB's accredited pharmacy directory is publicly searchable. Accreditation status can lapse if a pharmacy fails its renewal survey, so current status should be confirmed directly through URAC's directory rather than relying on any pharmacy's self-reported marketing.

USP Chapter Compliance

USP <797> governs sterile compounding and is the chapter most relevant to Help's injectable products. The 2023 revision of USP <797> tightened requirements for Beyond-Use Dating (BUD), environmental monitoring, personnel training, and contamination risk categorization. A pharmacy that was compliant under the 2008 version of USP <797> may require significant process revision to meet the 2023 standard. PCAB accreditation surveys now assess against the 2023 revision, so a recently renewed PCAB accreditation is a stronger signal than one issued before 2024.

Limits of PCAB Accreditation

PCAB accreditation is not FDA approval. It does not mean the FDA has evaluated or approved any specific compounded product for safety or efficacy. The FDA has stated explicitly that compounded drugs are not FDA-approved and have not undergone the clinical review process that approved drugs like semaglutide injection (Wegovy) or tirzepatide injection (Zepbound) have completed.

LegitScript Status and Independent Pharmacy Verification

LegitScript operates a voluntary pharmacy certification program that evaluates whether online pharmacies comply with applicable laws and professional standards. Certification requires disclosure of physical address, pharmacist credentials, prescription requirements, and privacy practices.

As of this review, Help Pharmacy does not carry active LegitScript certification. The absence of LegitScript certification is not itself evidence of illegal activity, because many legitimate compounding pharmacies have not pursued it. However, telehealth platforms that use LegitScript certification as a baseline vendor qualification standard will not be able to add Help to their pharmacy network without a manual exception review.

The HealthRX pharmacy qualification framework scores compounders across six domains: state board standing, FDA 503B compliance history, PCAB accreditation, LegitScript status, BBB complaint ratio, and product-specific quality documentation. Help scores green on state board standing and PCAB, yellow on FDA 503B history (Form 483 observations, no consent decree), yellow on LegitScript (not certified), and requires case-by-case evaluation on product-specific quality documentation for sterile injectables. Prescribers using this framework should request a current Certificate of Analysis (COA) and sterility test result for each lot of any injectable product dispensed by Help.

BBB Profile and Patient Complaints

The Better Business Bureau (BBB) profile for Help Pharmacy is publicly accessible at bbb.org. BBB accreditation indicates a business has agreed to meet BBB standards for trust, which include prompt complaint response and transparent business practices.

Complaint Volume and Categories

Help's BBB profile shows a pattern of complaints consistent with a high-volume mail-order pharmacy: shipping delays, temperature excursion concerns during transit, billing disputes, and product potency questions. For a pharmacy shipping temperature-sensitive sterile injectables across the country, cold-chain complaints warrant particular attention. Semaglutide and other peptide compounds may degrade if exposed to temperatures above 8 degrees Celsius during transit, potentially reducing potency without any visible change to the vial.

Interpreting Complaint Data

Raw complaint counts must be adjusted for volume. A pharmacy shipping hundreds of thousands of orders per month will accumulate more BBB complaints in absolute terms than a small regional compounder, even if the per-order complaint rate is similar. Neither the BBB nor Help publicly discloses prescription volume, making a normalized complaint rate difficult to calculate. What is meaningful: the ratio of resolved to unresolved complaints and the nature of the company's responses. Prescribers should review the most recent 12 months of BBB complaints before routing new patient prescriptions to any compounding pharmacy.

Clinical Products: GLP-1, HRT, TRT, and Peptides

Help is best known in telehealth circles for three product categories.

Compounded Semaglutide and Tirzepatide

Compounded semaglutide from a 503B facility was legal during the FDA shortage period. The STEP-1 trial (N=1,961) showed that FDA-approved semaglutide 2.4 mg subcutaneous injection produced 14.9% mean body weight loss at 68 weeks versus 2.4% for placebo (P<0.001). Wilding et al., NEJM 2021. Compounded semaglutide is not the same product and has not been evaluated in that trial or any equivalent trial. The active pharmaceutical ingredient (API) used in 503B compounding must come from an FDA-registered facility, but the finished compounded product has not undergone the bioavailability testing that confirmed the STEP-1 dose-response relationship.

The same regulatory logic applies to compounded tirzepatide. The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% placebo. Jastreboff et al., NEJM 2022. Neither Help nor any compounding pharmacy has conducted equivalent pharmacokinetic bridging studies.

Testosterone and HRT

Compounded testosterone cypionate and testosterone enanthate are 503A products, meaning each vial requires a patient-specific prescription. Compounded bioidentical HRT (estradiol, progesterone) falls in a similar category. The Endocrine Society's 2019 clinical practice guideline on testosterone therapy in men notes that "compounded testosterone preparations are not FDA approved and their safety and efficacy have not been established in controlled clinical trials." That statement from a major guideline document is a disclosure all prescribers should make to patients receiving compounded testosterone from any source.

Peptides Including BPC-157

BPC-157 (body protection compound 157) is not FDA-approved for any indication. The FDA has stated that peptides including BPC-157, TB-500, and others may not be compounded under either 503A or 503B pathways when they are not FDA-approved bulk drug substances on the 503A bulks list or the 503B bulks list. The FDA's current 503A bulks list and 503B bulks list are the controlling documents. Prescribers and patients should verify that any peptide ordered from Help is on the applicable bulks list at the time of dispensing.

How to Independently Verify Help's Credentials Right Now

Any prescriber or patient can complete this five-step verification in under 20 minutes.

1. Texas State Board of Pharmacy. Search the TSBP license verification portal for Help Pharmacy. Confirm the permit is active and check the disciplinary history tab.

2. FDA 503B Registered Facility List. Confirm Help appears on the FDA's current outsourcing facility list.

3. FDA Inspection Database. Search Help's facility in the FDA's warning letter database and the EIR database for Form 483 records.

4. PCAB / URAC Directory. Confirm current accreditation status at urac.org.

5. BBB Profile. Review complaint history and resolution patterns at bbb.org.

Request a current COA and sterility/endotoxin test report for any sterile injectable lot before dispensing or administering.

What Clinicians Should Ask Before Prescribing Through Help

Prescribers carry legal and ethical responsibility for the quality of compounded products they order. Four direct questions cut through marketing claims.

First, ask for the API supplier's FDA registration number for any sterile injectable product. Second, ask for the most recent sterility test and endotoxin test results for the specific lot number you are ordering. Third, ask whether the specific compound you are ordering is legally permissible under the current FDA shortage list or bulks list status. Fourth, ask for documentation that the cold-chain shipping method has been validated for the geographic route and season.

The American Society of Health-System Pharmacists (ASHP) published a position statement noting that "prescribers should obtain quality assurance documentation from compounding pharmacies before routing patient prescriptions." That standard applies equally to telehealth prescribers ordering remotely at scale.